ArticleBriefings in bioinformatics2026
EpiXFormer: a cross-attention neural network for predicting cell type-specific transcription factor binding sites.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Transcription factors (TFs) bind to specific sequences in the genome to regulate gene expression and specify cell states. TF binding sites (TFBSs) are cell type-specific, which can be attributed to epigenomic contexts. Comprehensive profiling of TFBSs across various cell types through experimental approaches is neither practical nor cost-friendly. Accurately identifying cell type-specific TFBSs through computational approaches remains challenging. Here, we develop EpiXFormer, a novel transformer-based neural network for cell type-specific TFBS prediction. EpiXFormer achieves exceptional performance in predicting binding sites of DNA-binding proteins (DBPs) across a diverse collection of cell types. It models the effects of proximal and distal epigenomic information on DBP binding and learns the identified motifs of the examined TFs and their potential co-occurring proteins. Moreover, we demonstrate that EpiXFormer can infer pioneer factors during cell type transition and delineate the cell type-specific regulatory functions of TFs. Overall, EpiXFormer enables cell type-specific TFBS prediction in the examined cell lines and is readily applied to other cell types of interest. It provides a robust, scalable framework for characterizing and interpreting multimodal genomic data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.